

3. (Original) The method of claim 1, wherein the interleukin-11 is administered daily until improvement of the disorder is observed.

4. (Original) The method of claim 1, wherein the interleukin-11 is administered daily until remission of the disorder is observed.

5. (Original) The method of claim 1, wherein the gastrointestinal disorder is gastroesophageal reflux disease.

6. (Original) The method of claim 1, wherein the gastrointestinal motility disorder is post-operative adynamic ileus.

7. (Original) The method of claim 1, wherein said subject is a preterm infant and said gastrointestinal disorder is intolerance to oral feeding.

8. (Original) A method of preventing the onset of a gastrointestinal disorder in a mammal which comprises administering to the mammal a therapeutically effective amount of interleukin-11, wherein said gastrointestinal disorder is selected from the group consisting of gastroesophageal reflux disease, post-operative adynamic ileus and intolerance to oral feeding.

Applicants: Keith et al.
U.S.S.N. 09/920,532

9. (Original) The method of claim 8, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 1000 μg /kg body weight.

Claims 10-13 (Cancelled)

Claim 14 (New) The method of claim 1, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 μg /kg body weight.

Claim 15 (New) The method of claim 8, wherein the therapeutically effective amount of interleukin-11 comprises 1 to 100 μg /kg body weight.